Avatar photo

Ron Finklestien

Palantir’s AIP Platform Experiences Rapid Enterprise Growth

Palantir Technologies (PLTR) reported a 71% year-over-year increase in U.S. commercial revenue for Q1 2025, surpassing a $1 billion annual run rate for the ...

Two Stocks Poised to Quintuple Your Investment by 2030

Over the past five years, growth stocks like Nvidia and Tesla have seen significant gains, but analysts suggest that underappreciated stocks such as Coupang ...

Why Meta Platforms Stands Out as the Top AI Investment Among the Magnificent Seven

As of 2025, the S&P 500 index is up 1%, driven by a strong first-quarter earnings season despite economic and trade policy concerns. Meta ...

Stock Spotlight: Trend Micro (TMICY) on the Rise

Trend Micro Inc. (TMICY) has surged more than 40% in 2023, outperforming many of its cybersecurity peers like CrowdStrike and Zscaler. The company’s success ...

Stock Analysis Spotlight: IPG Photonics (IPGP)

IPG Photonics Corporation (IPGP) has seen its stock price fall 30% year-to-date, attributed to declining earnings estimates and reduced demand for its laser systems. ...

Warren Buffett Allocates 32% of $281 Billion Berkshire Hathaway in Two Key S&P 500 Dividend Stocks

Warren Buffett, the CEO of Berkshire Hathaway, will resign at the end of this year, concluding decades of leadership that have significantly outperformed the ...

A.I. Stock Set to Outperform Apple by 2025

Apple’s market capitalization has declined to $3 trillion, lagging behind competitors Microsoft and Nvidia, while Amazon has surged to a market cap of $2.18 ...

Bitcoin’s Path to $1 Million: What to Expect During the Trump Era

At the recent Bitcoin 2025 conference in Las Vegas, billionaire Arthur Hayes predicted that Bitcoin could reach $1 million as early as 2028. Currently ...

Evaluating Palantir’s Value Amidst Increasing Government Contracts

Palantir Technologies (NASDAQ: PLTR) saw its stock surge by approximately 7% on Friday following a report from The New York Times indicating that the ...

The Future of Merck: Assessing Keytruda’s Role in Sustained Growth

Merck’s leading drug, Keytruda, experienced a significant sales increase of 72%, rising from $17 billion in 2021 to $29 billion in 2022, now accounting ...